Graphene: an enticing prospect for pharma R&D

21 September 2015
graphene-big

By Phil Taylor, a freelance journalist covering the healthcare, science and technology sectors

A wonder material that consists simply of sheets of carbon atoms is making waves across the scientific community, and that includes researchers in the life sciences.

Called graphene, the material is one of the thinnest and strongest materials known to man and earned its discoverers - Andre Geim and Konstantin Novoselov of the University of Manchester - the Nobel Prize for Physics in 2010.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight